These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23189850)

  • 61. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
    Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
    World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
    Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
    Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.
    Di Marco V; Calvaruso V; Grimaudo S; Ferraro D; Pipitone RM; Di Stefano R; Craxì A
    J Viral Hepat; 2013 Feb; 20(2):113-21. PubMed ID: 23301546
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.
    Murata K; Sugiyama M; Kimura T; Yoshio S; Kanto T; Kirikae I; Saito H; Aoki Y; Hiramine S; Matsui T; Ito K; Korenaga M; Imamura M; Masaki N; Mizokami M
    J Gastroenterol; 2014 Jan; 49(1):126-37. PubMed ID: 23591768
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Evaluation of the antiviral therapy for chronic hepatitis C in patients unresponsive to previous treatment with regard to the interleukin-28B genotypes].
    Fazylov VCh; Tkacheva SV; Manapova ER; Jakupova FM
    Vopr Virusol; 2015; 60(1):28-31. PubMed ID: 26021070
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Correlation Study Between IL-28B Gene Polymorphism (rs8099917SNP) and Sustained Virological Response in Iranian Patients with Chronic Hepatitis C.
    Larijani MS; Sadat SM; Nikbin M; Talebi SS; Javadi F; Mohajel N; Bolhassani A; Daneshvar M; Aghasadeghi MR; Pouriayevali MH; Mapar M
    Clin Lab; 2016; 62(3):417-23. PubMed ID: 27156332
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients.
    Alborzi A; Hashempour T; Moayedi J; Musavi Z; Pouladfar G; Merat S
    Med Microbiol Immunol; 2017 Apr; 206(2):165-174. PubMed ID: 28214926
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Associations between responses to interferon therapy and genetic variation in interleukin-28B and the core region of hepatitis C virus genotype 3a.
    Yamada K; Ishigami M; Kuzuya T; Honda T; Hayashi K; Goto H
    J Med Virol; 2015 Aug; 87(8):1361-7. PubMed ID: 25907669
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Immunogenetic predictors of a rapid virologic response to antiviral therapy in patients with chronic hepatitis C].
    Yushchuk ND; Znoiko OO; Balmasova IP; Fedoseyeva NV; Shmeleva EV; Dudina KR; Klimova EA; Petrova TV; Trofimov DY; Belyi PA; Safiullina NKh; Pypkina EV
    Ter Arkh; 2012; 84(11):11-7. PubMed ID: 23252241
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inherent transcriptional signatures of NK cells are associated with response to IFNα + rivabirin therapy in patients with Hepatitis C Virus.
    Ascierto ML; Bozzano F; Bedognetti D; Marras F; Schechterly C; Matsuura K; Picciotto A; Marenco S; Zhao Y; DeGiorgi V; Sommariva M; Moretta L; Wang E; Alter HJ; Marincola FM; De Maria A
    J Transl Med; 2015 Mar; 13():77. PubMed ID: 25849716
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Novel findings for the development of drug therapy for various liver diseases: Genetic variation in IL-28B is associated with response to the therapy for chronic hepatitis C.
    Sugiyama M; Tanaka Y; Nakanishi M; Mizokami M
    J Pharmacol Sci; 2011; 115(3):263-9. PubMed ID: 21350308
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Genetic variation of the IL-28B promoter affecting gene expression.
    Sugiyama M; Tanaka Y; Wakita T; Nakanishi M; Mizokami M
    PLoS One; 2011; 6(10):e26620. PubMed ID: 22046316
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Introduction to the genetics and biology of interleukin-28B.
    Urban T; Charlton MR; Goldstein DB
    Hepatology; 2012 Jul; 56(1):361-6. PubMed ID: 22511448
    [No Abstract]   [Full Text] [Related]  

  • 75. [Studies on the relationship between polymorphism of IL-28B rs8099917 and the outcome of HBV infection].
    Jiao XL; Gao YT; Jing L; Liu T; Shi WX; Guo H; Yang B; DU Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Nov; 32(11):1143-7. PubMed ID: 22336553
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Significance of allelic variants of interleukin-28B gene in chronic hepatitis C].
    Tikhonova NIu; Burnevich ÉZ; Krasnova TN
    Ter Arkh; 2013; 85(12):106-13. PubMed ID: 24640679
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [IL28B genetic variation and hepatic ISGs expression predict treatment efficacy of IFN-based anti-viral therapy for chronic hepatitis C].
    Honda M; Kaneko S
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():178-83. PubMed ID: 26845926
    [No Abstract]   [Full Text] [Related]  

  • 78. Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C.
    Huang JF; Huang CK; Yu ML; Dai CY; Huang CF; Hung WW; Yeh ML; Hsieh MH; Yang JF; Hsieh MY; Lin ZY; Chen SC; Wu SS; Chuang WL
    Hepatol Int; 2012 Jun; 6(3):613-9. PubMed ID: 22020824
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Genetic variant links hepatitis C virus clearance and treatment response.
    McBride D
    ONS Connect; 2013 Mar; 28(1):50. PubMed ID: 23495532
    [No Abstract]   [Full Text] [Related]  

  • 80. Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients.
    Chen H; Zhang Y; Huang P; Xu Y; Wang J; Su J; Yu R
    J Biomed Res; 2014 Nov; 28(6):476-83. PubMed ID: 25469117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.